Keenova Therapeutics plc Interest Expense Nonoperating
Keenova Therapeutics plc reported Interest Expense Nonoperating of $51.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Keenova Therapeutics plc interest expense nonoperating for the quarter ending 2026-06-30 was $51.20M, a 57.54% increase year-over-year.
- Keenova Therapeutics plc interest expense nonoperating for the quarter ending 2026-03-31 was $51.00M, a 56.44% increase year-over-year.
- Keenova Therapeutics plc interest expense nonoperating for the quarter ending 2025-12-31 was $32.80M, a 34.79% decline year-over-year.
- Keenova Therapeutics plc interest expense nonoperating for the quarter ending 2025-09-26 was $70.60M, a 19.66% increase year-over-year.
- Keenova Therapeutics plc interest expense nonoperating for fiscal 2025 was $168.80M, a 25.90% decline from fiscal 2024.
- Keenova Therapeutics plc interest expense nonoperating for fiscal 2024 was $227.80M.
| Period end | Interest Expense Nonoperating 1 month | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 10 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $51.20M 10-Q · filed 2026-08-11 | $102.20M 10-Q · filed 2026-08-11 | $135.00M derived: sum of 3 quarters · filed 2026-08-11 | $205.60M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $51.00M 10-Q · filed 2026-05-12 | $83.80M derived: sum of 2 quarters · filed 2026-05-12 | $154.40M derived: sum of 3 quarters · filed 2026-05-12 | $186.90M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | $32.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $103.40M derived: sum of 2 quarters · filed 2026-04-15 | $135.90M derived: sum of 3 quarters · filed 2026-08-11 | $168.80M 10-K · filed 2026-04-15 | ||
| 2025-09-26 | $70.60M 10-Q · filed 2025-11-10 | $103.10M derived: sum of 2 quarters · filed 2026-08-11 | $136.00M 10-Q · filed 2025-11-10 | $186.00M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-27 | $32.50M 10-Q · filed 2026-08-11 | $65.10M 10-Q · filed 2026-08-11 | $115.40M derived: sum of 3 quarters · filed 2026-08-11 | $174.40M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-28 | $32.60M 10-Q · filed 2026-05-12 | $82.90M derived: sum of 2 quarters · filed 2026-05-12 | $141.90M derived: sum of 3 quarters · filed 2026-05-12 | |||
| 2024-12-27 | $50.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $109.30M derived: sum of 2 quarters · filed 2026-04-15 | $227.80M 10-K · filed 2026-04-15 | |||
| 2024-09-27 | $59.00M 10-Q · filed 2025-11-10 | $177.50M 10-Q · filed 2025-11-10 | ||||
| 2023-12-29 | $28.30M 10-K · filed 2026-04-15 | |||||
| 2023-11-14 | $410.70M 10-K · filed 2026-04-15 |